NO20052796D0 - Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese - Google Patents
Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogeneseInfo
- Publication number
- NO20052796D0 NO20052796D0 NO20052796A NO20052796A NO20052796D0 NO 20052796 D0 NO20052796 D0 NO 20052796D0 NO 20052796 A NO20052796 A NO 20052796A NO 20052796 A NO20052796 A NO 20052796A NO 20052796 D0 NO20052796 D0 NO 20052796D0
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- indolylpyrazinone
- angiogenesis
- treatment
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42549002P | 2002-11-12 | 2002-11-12 | |
US46091503P | 2003-04-07 | 2003-04-07 | |
US48420203P | 2003-06-30 | 2003-06-30 | |
PCT/US2003/036003 WO2004043950A1 (en) | 2002-11-12 | 2003-11-10 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052796L NO20052796L (no) | 2005-06-09 |
NO20052796D0 true NO20052796D0 (no) | 2005-06-09 |
Family
ID=32314888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052796A NO20052796D0 (no) | 2002-11-12 | 2005-06-09 | Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1565455A1 (no) |
JP (1) | JP2006509840A (no) |
KR (1) | KR20050072824A (no) |
AR (1) | AR043059A1 (no) |
AU (1) | AU2003290744A1 (no) |
BR (1) | BR0316169A (no) |
CA (1) | CA2505819A1 (no) |
EC (1) | ECSP055851A (no) |
HR (1) | HRP20050496A2 (no) |
MA (1) | MA27557A1 (no) |
MX (1) | MXPA05004779A (no) |
NO (1) | NO20052796D0 (no) |
PE (1) | PE20040832A1 (no) |
PL (1) | PL376867A1 (no) |
TW (1) | TW200418834A (no) |
UY (1) | UY28074A1 (no) |
WO (1) | WO2004043950A1 (no) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005054201A1 (en) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
CN1882549B (zh) | 2003-11-20 | 2011-02-23 | 詹森药业有限公司 | 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮 |
US20070105851A1 (en) * | 2003-11-21 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキナゾリンジオン誘導体 |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
BRPI0512902A (pt) | 2004-06-30 | 2008-04-15 | Janssen Pharmaceutica Nv | derivados de ftalazina como inibidores de parp |
CA2587891C (en) | 2004-11-17 | 2010-08-31 | Rexhan Pharmaceuticals, Inc. | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)alylpiperazine derivatives |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
ES2381446T3 (es) | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
DK2271626T3 (en) | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN |
US20100113461A1 (en) * | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
US20100113514A1 (en) | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
JP2012508250A (ja) * | 2008-11-07 | 2012-04-05 | ワイス・エルエルシー | キノキサリン系のlxrモジュレーター |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
CA2943687C (en) | 2014-03-26 | 2024-02-13 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
WO2015144804A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations |
EP3131881A4 (en) * | 2014-04-18 | 2017-09-06 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
JP6898919B2 (ja) | 2015-09-23 | 2021-07-07 | ヤンセン ファーマシューティカ エヌ.ベー. | 新規化合物 |
CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
IL311717A (en) * | 2021-09-29 | 2024-05-01 | Repare Therapeutics Inc | 1,3,4-disubstituted thiazolyl or thiazolyl-disubstituted carboxamide for inhibition of human theta polymerase |
WO2024069592A1 (en) * | 2022-09-29 | 2024-04-04 | Repare Therapeutics Inc. | N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/es unknown
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/ja active Pending
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/en active Application Filing
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/es not_active Application Discontinuation
- 2003-11-10 EP EP03783328A patent/EP1565455A1/en not_active Withdrawn
- 2003-11-10 CA CA002505819A patent/CA2505819A1/en not_active Abandoned
- 2003-11-10 PL PL376867A patent/PL376867A1/pl unknown
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/pt not_active Application Discontinuation
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/ko not_active Application Discontinuation
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/es not_active Application Discontinuation
- 2003-11-11 TW TW092131443A patent/TW200418834A/zh unknown
- 2003-11-11 UY UY28074A patent/UY28074A1/es not_active Application Discontinuation
-
2005
- 2005-06-02 HR HR20050496A patent/HRP20050496A2/hr not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/fr unknown
- 2005-06-09 NO NO20052796A patent/NO20052796D0/no not_active Application Discontinuation
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP055851A (es) | 2005-09-20 |
KR20050072824A (ko) | 2005-07-12 |
TW200418834A (en) | 2004-10-01 |
AR043059A1 (es) | 2005-07-13 |
HRP20050496A2 (en) | 2006-06-30 |
PL376867A1 (pl) | 2006-01-09 |
NO20052796L (no) | 2005-06-09 |
MA27557A1 (fr) | 2005-10-03 |
CA2505819A1 (en) | 2004-05-27 |
EP1565455A1 (en) | 2005-08-24 |
BR0316169A (pt) | 2005-09-27 |
MXPA05004779A (es) | 2005-07-22 |
PE20040832A1 (es) | 2005-01-27 |
WO2004043950A1 (en) | 2004-05-27 |
JP2006509840A (ja) | 2006-03-23 |
AU2003290744A1 (en) | 2004-06-03 |
UY28074A1 (es) | 2004-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052796D0 (no) | Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese | |
NO20055152D0 (no) | Karbonstyrilderivater og humor stabiliserende midler for behandling av humor forstyrrelser | |
NO20052894D0 (no) | 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte | |
NO20051493D0 (no) | Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme | |
HK1079203A1 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders | |
HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
NO20031626L (no) | Pyridonderivater for behandling av atherosklerose | |
NO20013380L (no) | 2-aminobenzoksazinonderivater for behandling av fedme | |
GB0312832D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
NO20041216L (no) | Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt | |
HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
NO20052009D0 (no) | Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom | |
AU2003284808A8 (en) | The derivatives of pyridone and the use of them | |
NO20032801D0 (no) | Tiazolderivater for behandling av PPAR relaterte forstyrrelser | |
NO20043237L (no) | Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser | |
IS2907B (is) | Bensó[d]asepínafleiður til að meðhöndla taugakvilla | |
NO20050569D0 (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
NO20051503D0 (no) | Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. | |
DE60319951D1 (de) | Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate | |
HK1087103A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
NO20013381D0 (no) | 2-oksybenzoksazinonderivater for behandling av fedme | |
NO20026263L (no) | Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser | |
NO20032636D0 (no) | 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser | |
NO20043986L (no) | Velsmakende oral suspensjon og framgangsmate for fremstilling av suspensjonen. | |
NO20024775D0 (no) | Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |